Mark E. O’Malley

2.3k total citations
31 papers, 1.8k citations indexed

About

Mark E. O’Malley is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Mark E. O’Malley has authored 31 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 10 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Mark E. O’Malley's work include Virus-based gene therapy research (14 papers), CAR-T cell therapy research (10 papers) and Cancer Research and Treatments (4 papers). Mark E. O’Malley is often cited by papers focused on Virus-based gene therapy research (14 papers), CAR-T cell therapy research (10 papers) and Cancer Research and Treatments (4 papers). Mark E. O’Malley collaborates with scholars based in United States, China and United Kingdom. Mark E. O’Malley's co-authors include David L. Bartlett, Steven T. DeKosky, Zong Sheng Guo, Patrick M. Kochanek, James R. Goss, Herbert J. Zeh, Scot Styren, Paweł Kaliński, Donald W. Marion and Padma Sampath and has published in prestigious journals such as Nature Medicine, Journal of Neuroscience and Cancer Research.

In The Last Decade

Mark E. O’Malley

31 papers receiving 1.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark E. O’Malley 800 715 552 373 286 31 1.8k
Mariana Puntel 644 0.8× 779 1.1× 427 0.8× 550 1.5× 195 0.7× 47 1.8k
Masashi Urabe 1.7k 2.1× 2.2k 3.0× 547 1.0× 267 0.7× 308 1.1× 98 3.3k
Eric M. Oshiro 517 0.6× 484 0.7× 338 0.6× 101 0.3× 375 1.3× 15 1.4k
Donna Armentano 1.3k 1.6× 1.4k 2.0× 313 0.6× 141 0.4× 525 1.8× 35 2.3k
Assumpció Bosch 977 1.2× 1.3k 1.9× 222 0.4× 137 0.4× 214 0.7× 79 2.3k
B Bödey 407 0.5× 866 1.2× 654 1.2× 553 1.5× 194 0.7× 93 2.0k
Kye Chesnut 1.3k 1.6× 1.2k 1.6× 256 0.5× 214 0.6× 255 0.9× 16 2.0k
Ann P. Chidgey 285 0.4× 738 1.0× 713 1.3× 2.0k 5.3× 192 0.7× 64 3.4k
Linda Yang 839 1.0× 2.1k 3.0× 290 0.5× 226 0.6× 171 0.6× 56 3.0k
Joseph R. Podojil 205 0.3× 606 0.8× 420 0.8× 1.2k 3.3× 162 0.6× 55 2.4k

Countries citing papers authored by Mark E. O’Malley

Since Specialization
Citations

This map shows the geographic impact of Mark E. O’Malley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. O’Malley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. O’Malley more than expected).

Fields of papers citing papers by Mark E. O’Malley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. O’Malley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. O’Malley. The network helps show where Mark E. O’Malley may publish in the future.

Co-authorship network of co-authors of Mark E. O’Malley

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. O’Malley. A scholar is included among the top collaborators of Mark E. O’Malley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. O’Malley. Mark E. O’Malley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gurevich, Irina, Pooja Agarwal, Henry Liu, et al.. (2022). In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nature Medicine. 28(4). 780–788. 99 indexed citations
2.
Freedman, John C., Trevor J. Parry, Avijit Majumdar, et al.. (2020). Preclinical Evaluation of a Modified Herpes Simplex Virus Type 1 Vector Encoding Human TGM1 for the Treatment of Autosomal Recessive Congenital Ichthyosis. Journal of Investigative Dermatology. 141(4). 874–882.e6. 20 indexed citations
3.
Downs‐Canner, Stephanie, Deepa Magge, Roshni Ravindranathan, et al.. (2015). Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer. Annals of Surgical Oncology. 23(2). 655–662. 33 indexed citations
4.
Zeh, Herbert J., Stephanie Downs‐Canner, J. Andrea McCart, et al.. (2014). First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity. Molecular Therapy. 23(1). 202–214. 120 indexed citations
5.
Thirunavukarasu, Pragatheeshwar, Magesh Sathaiah, Michael C. Gorry, et al.. (2013). A Rationally Designed A34R Mutant Oncolytic Poxvirus: Improved Efficacy in Peritoneal Carcinomatosis. Molecular Therapy. 21(5). 1024–1033. 24 indexed citations
6.
Magge, Deepa, et al.. (2013). Inhibitors of C5 complement enhance vaccinia virus oncolysis. Cancer Gene Therapy. 20(6). 342–350. 21 indexed citations
7.
Choudry, Haroon A., Arun Mavanur, Mark E. O’Malley, et al.. (2012). Chronic Anti-inflammatory Drug Therapy Inhibits Gel-Forming Mucin Production in a Murine Xenograft Model of Human Pseudomyxoma Peritonei. Annals of Surgical Oncology. 19(5). 1402–1409. 18 indexed citations
8.
Li, Jun, Mark E. O’Malley, Padma Sampath, et al.. (2012). Expression of CCL19 from Oncolytic Vaccinia Enhances Immunotherapeutic Potential while Maintaining Oncolytic Activity. Neoplasia. 14(12). 1115–IN1. 53 indexed citations
9.
Choudry, Haroon A., Mark E. O’Malley, Zong Sheng Guo, Herbert J. Zeh, & David L. Bartlett. (2012). Mucin as a therapeutic target in pseudomyxoma peritonei. Journal of Surgical Oncology. 106(7). 911–917. 25 indexed citations
10.
Li, Jun, Mark E. O’Malley, Julie Urban, et al.. (2011). Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer. Molecular Therapy. 19(4). 650–657. 115 indexed citations
11.
Sathaiah, Magesh, Mark E. O’Malley, Roshni Ravindranathan, et al.. (2011). Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer. Cancer Gene Therapy. 19(3). 192–201. 10 indexed citations
12.
O’Gorman, William, Padma Sampath, Erin F. Simonds, et al.. (2010). Alternate Mechanisms of Initial Pattern Recognition Drive Differential Immune Responses to Related Poxviruses. Cell Host & Microbe. 8(2). 174–185. 24 indexed citations
13.
Ziauddin, M. Firdos, Zong Sheng Guo, Mark E. O’Malley, et al.. (2010). TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Therapy. 17(4). 550–559. 27 indexed citations
14.
Yang, Shaolong, Zong Sheng Guo, Mark E. O’Malley, et al.. (2007). A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Gene Therapy. 14(8). 638–647. 22 indexed citations
15.
Chalikonda, Sricharan, Mark E. O’Malley, Xiaopeng Dong, et al.. (2007). Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Therapy. 15(2). 115–125. 61 indexed citations
16.
17.
Goss, James R., Marina Mata, Mark E. O’Malley, et al.. (2002). Herpes vector–mediated expression of proenkephalin reduces bone cancer pain. Annals of Neurology. 52(5). 662–665. 85 indexed citations
18.
Goss, James R., Mark E. O’Malley, Lanling Zou, et al.. (1998). Astrocytes Are the Major Source of Nerve Growth Factor Upregulation Following Traumatic Brain Injury in the Rat. Experimental Neurology. 149(2). 301–309. 130 indexed citations
19.
DeKosky, Steven T., Scot Styren, Mark E. O’Malley, et al.. (1996). Interleukm‐1 receptor antagonist suppresses neurotrophin response in injured rat brain. Annals of Neurology. 39(1). 123–127. 84 indexed citations
20.
Gasparro, Francis P., et al.. (1991). Photoactivatable Antisense DNA: Suppression of Ampicillin Resistance in Normally Resistant Escherichia coli. PubMed. 1(2). 117–140. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mariana Puntel Breakdown of academic impact, for papers by Masashi Urabe Breakdown of academic impact, for papers by Eric M. Oshiro Breakdown of academic impact, for papers by Donna Armentano Breakdown of academic impact, for papers by Assumpció Bosch Breakdown of academic impact, for papers by B Bödey Breakdown of academic impact, for papers by Kye Chesnut Breakdown of academic impact, for papers by Ann P. Chidgey Breakdown of academic impact, for papers by Linda Yang Breakdown of academic impact, for papers by Joseph R. Podojil
Rankless by CCL
2026